Development of Highly Potent GAT1 Inhibitors: Synthesis of Nipecotic Acid Derivatives with N‐Arylalkynyl Substituents

A new scaffold of highly potent and mGAT1‐selective inhibitors has been developed. Compounds in this class are characterized by an alkyne‐type spacer connecting nipecotic acid with an aromatic moiety. Preliminary evaluations made it apparent that a nipecotic acid derivative with an N‐butynyl linker...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:ChemMedChem 2017-03, Vol.12 (5), p.362-371
Hauptverfasser: Lutz, Toni, Wein, Thomas, Höfner, Georg, Wanner, Klaus T.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 371
container_issue 5
container_start_page 362
container_title ChemMedChem
container_volume 12
creator Lutz, Toni
Wein, Thomas
Höfner, Georg
Wanner, Klaus T.
description A new scaffold of highly potent and mGAT1‐selective inhibitors has been developed. Compounds in this class are characterized by an alkyne‐type spacer connecting nipecotic acid with an aromatic moiety. Preliminary evaluations made it apparent that a nipecotic acid derivative with an N‐butynyl linker and a terminal 2‐biphenyl residue exhibiting a binding affinity (pKi) of 7.61±0.03 to mGAT1 and uptake inhibition (pIC50) of 7.00±0.06 selective for mGAT1 could serve as a hit compound. Docking calculations for compounds based on this structure in an hGAT1 homology modeling study indicated binding affinities similar to or even higher than that of the well‐known mGAT1 inhibitor tiagabine. Synthesis of the designed compounds was readily carried out by two consecutive cross‐coupling reactions, giving flexible access to variously substituted biphenyl subunits. With an appropriate substitution pattern of the biphenyl moiety, the binding affinity of enantiopure (R)‐nipecotic acid derivatives to mGAT1 increased to pKi=8.33±0.01, and the uptake inhibitory potency up to pIC50=7.72±0.02. Stable alkyne‐type spacer: A series of N‐substituted nipecotic acid derivatives with various 2‐biphenyl moieties attached via an N‐alkynyl linker were synthesized as potential GAT1 inhibitors. Some 2′,4′‐disubstituted derivatives were found to be highly potent in binding and uptake assays and display high subtype selectivity for GAT1.
doi_str_mv 10.1002/cmdc.201600599
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1877818120</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1877818120</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4069-ea7e15d8417b7b4c5ee25bbff9ac9a06e357826aba5ca0a6342367f722fcf72e3</originalsourceid><addsrcrecordid>eNqNkU9v0zAYh60JxMbguiOyxIVLi-0kdsytamGbtD9IG-fIcd9QDyfubKdVbvsI-4x8Ehx1dNIucHn9ynr8SP79EDqhZEoJYZ91u9RTRignpJDyAB3RkpOJoKV4td-FPERvQ7gjJM9LWr5Bh6ykrKA8P0LbBWzAunULXcSuwWfm58oO-LuL48Xp7Jbi825lahOdD1_wzdDFFQQTRvbKrEG7aDSeabPEC_Bmo6LZQMBbE1f46vfD48wPVtlfQzdYfNPXIZrYJ3N4h143ygZ4_3Qeox_fvt7OzyYX16fn89nFROeEywkoAbRYljkVtahzXQCwoq6bRiotFeGQFaJkXNWq0IoonuUs46IRjDU6TciO0aedd-3dfQ8hVq0JGqxVHbg-VCkokTKhjPwHyhkrM0myhH58gd653nfpI6Mw55QzWSRquqO0dyF4aKq1N63yQ0VJNbZXje1V-_bSgw9P2r5uYbnH_9aVALkDtsbC8A9dNb9czJ_lfwB3nafz</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1874616295</pqid></control><display><type>article</type><title>Development of Highly Potent GAT1 Inhibitors: Synthesis of Nipecotic Acid Derivatives with N‐Arylalkynyl Substituents</title><source>MEDLINE</source><source>Wiley Online Library All Journals</source><creator>Lutz, Toni ; Wein, Thomas ; Höfner, Georg ; Wanner, Klaus T.</creator><creatorcontrib>Lutz, Toni ; Wein, Thomas ; Höfner, Georg ; Wanner, Klaus T.</creatorcontrib><description>A new scaffold of highly potent and mGAT1‐selective inhibitors has been developed. Compounds in this class are characterized by an alkyne‐type spacer connecting nipecotic acid with an aromatic moiety. Preliminary evaluations made it apparent that a nipecotic acid derivative with an N‐butynyl linker and a terminal 2‐biphenyl residue exhibiting a binding affinity (pKi) of 7.61±0.03 to mGAT1 and uptake inhibition (pIC50) of 7.00±0.06 selective for mGAT1 could serve as a hit compound. Docking calculations for compounds based on this structure in an hGAT1 homology modeling study indicated binding affinities similar to or even higher than that of the well‐known mGAT1 inhibitor tiagabine. Synthesis of the designed compounds was readily carried out by two consecutive cross‐coupling reactions, giving flexible access to variously substituted biphenyl subunits. With an appropriate substitution pattern of the biphenyl moiety, the binding affinity of enantiopure (R)‐nipecotic acid derivatives to mGAT1 increased to pKi=8.33±0.01, and the uptake inhibitory potency up to pIC50=7.72±0.02. Stable alkyne‐type spacer: A series of N‐substituted nipecotic acid derivatives with various 2‐biphenyl moieties attached via an N‐alkynyl linker were synthesized as potential GAT1 inhibitors. Some 2′,4′‐disubstituted derivatives were found to be highly potent in binding and uptake assays and display high subtype selectivity for GAT1.</description><identifier>ISSN: 1860-7179</identifier><identifier>EISSN: 1860-7187</identifier><identifier>DOI: 10.1002/cmdc.201600599</identifier><identifier>PMID: 28125164</identifier><language>eng</language><publisher>Germany: Wiley Subscription Services, Inc</publisher><subject>Binding Sites ; cross-coupling reactions ; GABA Plasma Membrane Transport Proteins - chemistry ; GABA Plasma Membrane Transport Proteins - metabolism ; GABA uptake inhibitors ; GABA Uptake Inhibitors - chemical synthesis ; GABA Uptake Inhibitors - chemistry ; GABA Uptake Inhibitors - metabolism ; HEK293 Cells ; Humans ; Inhibitory Concentration 50 ; Molecular Docking Simulation ; molecular modeling ; nipecotic acid ; Nipecotic Acids - chemical synthesis ; Nipecotic Acids - chemistry ; Nipecotic Acids - metabolism ; Protein Isoforms - antagonists &amp; inhibitors ; Protein Isoforms - metabolism ; Protein Structure, Tertiary ; Structure-Activity Relationship ; structure–activity relationships</subject><ispartof>ChemMedChem, 2017-03, Vol.12 (5), p.362-371</ispartof><rights>2017 Wiley‐VCH Verlag GmbH &amp; Co. KGaA, Weinheim</rights><rights>2017 Wiley-VCH Verlag GmbH &amp; Co. KGaA, Weinheim.</rights><rights>2017 Wiley-VCH Verlag GmbH &amp; Co. KGaA, Weinheim</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4069-ea7e15d8417b7b4c5ee25bbff9ac9a06e357826aba5ca0a6342367f722fcf72e3</citedby><cites>FETCH-LOGICAL-c4069-ea7e15d8417b7b4c5ee25bbff9ac9a06e357826aba5ca0a6342367f722fcf72e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fcmdc.201600599$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fcmdc.201600599$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28125164$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lutz, Toni</creatorcontrib><creatorcontrib>Wein, Thomas</creatorcontrib><creatorcontrib>Höfner, Georg</creatorcontrib><creatorcontrib>Wanner, Klaus T.</creatorcontrib><title>Development of Highly Potent GAT1 Inhibitors: Synthesis of Nipecotic Acid Derivatives with N‐Arylalkynyl Substituents</title><title>ChemMedChem</title><addtitle>ChemMedChem</addtitle><description>A new scaffold of highly potent and mGAT1‐selective inhibitors has been developed. Compounds in this class are characterized by an alkyne‐type spacer connecting nipecotic acid with an aromatic moiety. Preliminary evaluations made it apparent that a nipecotic acid derivative with an N‐butynyl linker and a terminal 2‐biphenyl residue exhibiting a binding affinity (pKi) of 7.61±0.03 to mGAT1 and uptake inhibition (pIC50) of 7.00±0.06 selective for mGAT1 could serve as a hit compound. Docking calculations for compounds based on this structure in an hGAT1 homology modeling study indicated binding affinities similar to or even higher than that of the well‐known mGAT1 inhibitor tiagabine. Synthesis of the designed compounds was readily carried out by two consecutive cross‐coupling reactions, giving flexible access to variously substituted biphenyl subunits. With an appropriate substitution pattern of the biphenyl moiety, the binding affinity of enantiopure (R)‐nipecotic acid derivatives to mGAT1 increased to pKi=8.33±0.01, and the uptake inhibitory potency up to pIC50=7.72±0.02. Stable alkyne‐type spacer: A series of N‐substituted nipecotic acid derivatives with various 2‐biphenyl moieties attached via an N‐alkynyl linker were synthesized as potential GAT1 inhibitors. Some 2′,4′‐disubstituted derivatives were found to be highly potent in binding and uptake assays and display high subtype selectivity for GAT1.</description><subject>Binding Sites</subject><subject>cross-coupling reactions</subject><subject>GABA Plasma Membrane Transport Proteins - chemistry</subject><subject>GABA Plasma Membrane Transport Proteins - metabolism</subject><subject>GABA uptake inhibitors</subject><subject>GABA Uptake Inhibitors - chemical synthesis</subject><subject>GABA Uptake Inhibitors - chemistry</subject><subject>GABA Uptake Inhibitors - metabolism</subject><subject>HEK293 Cells</subject><subject>Humans</subject><subject>Inhibitory Concentration 50</subject><subject>Molecular Docking Simulation</subject><subject>molecular modeling</subject><subject>nipecotic acid</subject><subject>Nipecotic Acids - chemical synthesis</subject><subject>Nipecotic Acids - chemistry</subject><subject>Nipecotic Acids - metabolism</subject><subject>Protein Isoforms - antagonists &amp; inhibitors</subject><subject>Protein Isoforms - metabolism</subject><subject>Protein Structure, Tertiary</subject><subject>Structure-Activity Relationship</subject><subject>structure–activity relationships</subject><issn>1860-7179</issn><issn>1860-7187</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkU9v0zAYh60JxMbguiOyxIVLi-0kdsytamGbtD9IG-fIcd9QDyfubKdVbvsI-4x8Ehx1dNIucHn9ynr8SP79EDqhZEoJYZ91u9RTRignpJDyAB3RkpOJoKV4td-FPERvQ7gjJM9LWr5Bh6ykrKA8P0LbBWzAunULXcSuwWfm58oO-LuL48Xp7Jbi825lahOdD1_wzdDFFQQTRvbKrEG7aDSeabPEC_Bmo6LZQMBbE1f46vfD48wPVtlfQzdYfNPXIZrYJ3N4h143ygZ4_3Qeox_fvt7OzyYX16fn89nFROeEywkoAbRYljkVtahzXQCwoq6bRiotFeGQFaJkXNWq0IoonuUs46IRjDU6TciO0aedd-3dfQ8hVq0JGqxVHbg-VCkokTKhjPwHyhkrM0myhH58gd653nfpI6Mw55QzWSRquqO0dyF4aKq1N63yQ0VJNbZXje1V-_bSgw9P2r5uYbnH_9aVALkDtsbC8A9dNb9czJ_lfwB3nafz</recordid><startdate>20170307</startdate><enddate>20170307</enddate><creator>Lutz, Toni</creator><creator>Wein, Thomas</creator><creator>Höfner, Georg</creator><creator>Wanner, Klaus T.</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7TK</scope><scope>7U7</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>K9.</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>20170307</creationdate><title>Development of Highly Potent GAT1 Inhibitors: Synthesis of Nipecotic Acid Derivatives with N‐Arylalkynyl Substituents</title><author>Lutz, Toni ; Wein, Thomas ; Höfner, Georg ; Wanner, Klaus T.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4069-ea7e15d8417b7b4c5ee25bbff9ac9a06e357826aba5ca0a6342367f722fcf72e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Binding Sites</topic><topic>cross-coupling reactions</topic><topic>GABA Plasma Membrane Transport Proteins - chemistry</topic><topic>GABA Plasma Membrane Transport Proteins - metabolism</topic><topic>GABA uptake inhibitors</topic><topic>GABA Uptake Inhibitors - chemical synthesis</topic><topic>GABA Uptake Inhibitors - chemistry</topic><topic>GABA Uptake Inhibitors - metabolism</topic><topic>HEK293 Cells</topic><topic>Humans</topic><topic>Inhibitory Concentration 50</topic><topic>Molecular Docking Simulation</topic><topic>molecular modeling</topic><topic>nipecotic acid</topic><topic>Nipecotic Acids - chemical synthesis</topic><topic>Nipecotic Acids - chemistry</topic><topic>Nipecotic Acids - metabolism</topic><topic>Protein Isoforms - antagonists &amp; inhibitors</topic><topic>Protein Isoforms - metabolism</topic><topic>Protein Structure, Tertiary</topic><topic>Structure-Activity Relationship</topic><topic>structure–activity relationships</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lutz, Toni</creatorcontrib><creatorcontrib>Wein, Thomas</creatorcontrib><creatorcontrib>Höfner, Georg</creatorcontrib><creatorcontrib>Wanner, Klaus T.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>ChemMedChem</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lutz, Toni</au><au>Wein, Thomas</au><au>Höfner, Georg</au><au>Wanner, Klaus T.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Development of Highly Potent GAT1 Inhibitors: Synthesis of Nipecotic Acid Derivatives with N‐Arylalkynyl Substituents</atitle><jtitle>ChemMedChem</jtitle><addtitle>ChemMedChem</addtitle><date>2017-03-07</date><risdate>2017</risdate><volume>12</volume><issue>5</issue><spage>362</spage><epage>371</epage><pages>362-371</pages><issn>1860-7179</issn><eissn>1860-7187</eissn><abstract>A new scaffold of highly potent and mGAT1‐selective inhibitors has been developed. Compounds in this class are characterized by an alkyne‐type spacer connecting nipecotic acid with an aromatic moiety. Preliminary evaluations made it apparent that a nipecotic acid derivative with an N‐butynyl linker and a terminal 2‐biphenyl residue exhibiting a binding affinity (pKi) of 7.61±0.03 to mGAT1 and uptake inhibition (pIC50) of 7.00±0.06 selective for mGAT1 could serve as a hit compound. Docking calculations for compounds based on this structure in an hGAT1 homology modeling study indicated binding affinities similar to or even higher than that of the well‐known mGAT1 inhibitor tiagabine. Synthesis of the designed compounds was readily carried out by two consecutive cross‐coupling reactions, giving flexible access to variously substituted biphenyl subunits. With an appropriate substitution pattern of the biphenyl moiety, the binding affinity of enantiopure (R)‐nipecotic acid derivatives to mGAT1 increased to pKi=8.33±0.01, and the uptake inhibitory potency up to pIC50=7.72±0.02. Stable alkyne‐type spacer: A series of N‐substituted nipecotic acid derivatives with various 2‐biphenyl moieties attached via an N‐alkynyl linker were synthesized as potential GAT1 inhibitors. Some 2′,4′‐disubstituted derivatives were found to be highly potent in binding and uptake assays and display high subtype selectivity for GAT1.</abstract><cop>Germany</cop><pub>Wiley Subscription Services, Inc</pub><pmid>28125164</pmid><doi>10.1002/cmdc.201600599</doi><tpages>10</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1860-7179
ispartof ChemMedChem, 2017-03, Vol.12 (5), p.362-371
issn 1860-7179
1860-7187
language eng
recordid cdi_proquest_miscellaneous_1877818120
source MEDLINE; Wiley Online Library All Journals
subjects Binding Sites
cross-coupling reactions
GABA Plasma Membrane Transport Proteins - chemistry
GABA Plasma Membrane Transport Proteins - metabolism
GABA uptake inhibitors
GABA Uptake Inhibitors - chemical synthesis
GABA Uptake Inhibitors - chemistry
GABA Uptake Inhibitors - metabolism
HEK293 Cells
Humans
Inhibitory Concentration 50
Molecular Docking Simulation
molecular modeling
nipecotic acid
Nipecotic Acids - chemical synthesis
Nipecotic Acids - chemistry
Nipecotic Acids - metabolism
Protein Isoforms - antagonists & inhibitors
Protein Isoforms - metabolism
Protein Structure, Tertiary
Structure-Activity Relationship
structure–activity relationships
title Development of Highly Potent GAT1 Inhibitors: Synthesis of Nipecotic Acid Derivatives with N‐Arylalkynyl Substituents
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T20%3A53%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Development%20of%20Highly%20Potent%20GAT1%20Inhibitors:%20Synthesis%20of%20Nipecotic%20Acid%20Derivatives%20with%20N%E2%80%90Arylalkynyl%20Substituents&rft.jtitle=ChemMedChem&rft.au=Lutz,%20Toni&rft.date=2017-03-07&rft.volume=12&rft.issue=5&rft.spage=362&rft.epage=371&rft.pages=362-371&rft.issn=1860-7179&rft.eissn=1860-7187&rft_id=info:doi/10.1002/cmdc.201600599&rft_dat=%3Cproquest_cross%3E1877818120%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1874616295&rft_id=info:pmid/28125164&rfr_iscdi=true